Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3954068 · 1 trial · 1 indication
A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| LY3954068 (Part A) | EXPERIMENTAL | Single ascending dose of LY3954068 administered intrathecally (IT) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single ascending dose of placebo administered IT |
| LY3954068 (Part B) | EXPERIMENTAL | Multiple ascending dose of LY3954068 administered IT |
| Placebo (Part B) | PLACEBO_COMPARATOR | Multiple ascending dose of placebo administered IT |
| Name | Type | Description |
|---|---|---|
| LY3954068 | DRUG | Administered IT |
| Placebo | DRUG | Administered IT |
| Flortaucipir F18 | DRUG | Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan |
Inclusion Criteria: * Have a body mass index (BMI) within the range 18 to 40 kilograms per square meter (kg/m²), inclusive, at screening. * Have gradual and progressive change in memory function for greater than or equal to (≥) 6 months as reported by the participant or informant. * Have a mini men...
Top 20 of 24 competitors
LY3954068 is an investigational small molecule being developed for the treatment of Alzheimer's disease. It is currently in Phase 1 clinical development, with a first-in-human study enrolling participants with early symptomatic Alzheimer's disease.
The molecular target of LY3954068 has not been disclosed in available information. It is a small molecule being studied for its potential effects in Alzheimer's disease, but its specific mechanism of action is not publicly detailed.
LY3954068 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY.
LY3954068 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study is currently recruiting participants.
LY3954068 is being evaluated in a Phase 1 clinical trial with the identifier NCT06297590. This is a first-in-human study in participants with early symptomatic Alzheimer's disease, enrolling approximately 48 participants across the United States, Japan, and the United Kingdom.
No alternative names for LY3954068 have been disclosed. It is identified solely by its investigational code LY3954068 in clinical trial registries and company communications.